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PCV52
LOW LEVEL OF CONSISTENCY BETWEEN
QUALITATIVE (NCEP-II) AND QUANTITATIVE
METHODS TO RECOMMEND
PHARMACEUTICAL TREATMENT OF
HYPERCHOLESTEROLEMIA IN INDIVIDUALS
WITHOUT CORONARY HEART DISEASE
Plans-Rubió P
Departament de Sanitat of Catalonia, Barcelona, Spain
OBJECTIVE: The objective of this study was to assess
consistency between qualitative (NCEP-II) and quantita-
tive methods used to recommend cholesterol reduction 
in individuals without coronary heart disease in Spain.
METHODS: Qualitative (NCEP-II) and quantitative 
recommendations for cholesterol reduction were applied
to individuals without coronary heart disease (n = 304)
studied in a random sample of the adult population 
of Catalonia aged > years. Pharmaceutical treatment 
of hypercholesterolemia should be recommended for 
individuals with a LDL cholesterol concentration 
>190mg/dl or 160–189mg/dl with at least two other 
risk factors based on the NCEP-II method, and 
to individuals with a coronary heart disease risk in 10
years >20% based on the quantitative method. Dietary
treatment should be recommended for those detected
with the NCEP-II method and for those with a coronary
heart disease risk in 10 years >10%. Concordance
between both the qualitative and quantitative method
was assessed using the Kappa index. RESULTS: Pharma-
ceutical treatment of hypercholesterolemia should be rec-
ommended in 20,0% of men and 20,1% of women based
on the NCEP-II method and to 24% of men and 33,1%
based on the quantitative method. Concordance was low
(Kappa = 0,31) in men and moderate (Kappa = 0,45) in
women between the qualitative and quantitative method.
Hypercholesterolemia >240mg/dl was the main factor
explaining recommendations based on the NCEP-II
method (ORadj = 64), while age, hypertension and hyper-
cholesterolemia explained recommendations based on the
quantitative method. CONCLUSION: Results obtained
in this study showed a low concordance between quali-
tative and quantitative methods to recommend choles-
terol reduction in individuals without coronary heart
disease.
PCV53
INFLUENCE OF THREE HYPERTENSION
GUIDELINES ON RATES OF 
TREATMENT INDICATION
Rosery H1, Hense HW2
1Institute for Medical Outcome Research, Lorrach, Germany;
2University of Muenster, Muenster, Germany
OBJECTIVES: Three current guidelines for the manage-
ment of hypertension (JNC-VI 1997, WHO/ISH 1999,
BHS 1999) were compared with respect to their potential
impacts on rates of treatment indication. METHODS:
After systematic comparisons, the divergent recommen-
dations of the three guidelines were operationalized. 
Speciﬁc complex algorithms were developed for each
guideline to calculate the percentage of the population
with an indication for antihypertensive treatment (=
indication rates). Each guideline-speciﬁc algorithm was
applied to 10.460 men and women aged 35–74 from a
representative sample of the WHO-MONICA-Augsburg
study population. The computation was performed in
groups according to the risk strata of the three guidelines.
Additionally age-, gender- and blood-speciﬁc indication
rates were calculated. RESULTS: Each guideline uses
complex but different structures for the determination of
treatment indications. Generally, men had a higher treat-
ment rate than women independent of guideline applied.
Within each age decade, the guideline speciﬁc indication
rates differed by about ﬁve percent points. The age-
speciﬁc differences decreased with higher age within JNC,
were stable within WHO and increased within the BHS-
guideline. There were signiﬁcant differences of indication
rate by blood pressure categories below 160/90mmHg.
CONCLUSION: Different stringent conditions of anti-
hypertensive treatment indications are based on differing
inﬂuences of blood pressure, age and gender as potential
risk factors. The different risk stratiﬁcations may lead to
highly divergent economic consequences.
PCV54
SMOKING CESSATION: RELEVANCE IN THE
UNDER 25 GROUP
Taïeb C1, Piergiovanni J2, Myon E1
1Programmes Pharmaco Economiques Pierre Fabre, Boulogne
Billancourt, France; 2Centre de Formation Ste Cecile,
Albi, France
OBJECTIVE: As part of an “outcomes program” on
smoking cessation, we thought it relevant to evaluate in
smokers under 25 years of age the obstacles to cessation,
the level of dependency, the knowledge of tobacco depen-
dency and the propensity to pay for cessation treatment.
METHOD: For this pilot phase, an anonymous ques-
tionnaire was distributed in the “Student” supplement 
of a French regional weekly newspaper (Tarn Libre).
RESULTS: Obstacles to cessation: lack of willpower
(51%), enjoyment of smoking (32%), force of habit
(46%). The level of dependency on tobacco was evalu-
ated using the Fagerström test: 48% had low dependency,
48% moderate dependency and 2% high dependency. 
In general, our sample population had a good general
knowledge and understanding of tobacco use (number 
of premature deaths per year, percentage of smokers in
France, cost of tobacco for health insurance). Average
daily tobacco expenses were €2.3 (roughly corresponding
to an average consumption of 10 cigarettes/day), and the
subjects declared themselves ready to pay around €83 to
stop smoking (€157 in older adults). This ﬁgure is rela-
tively low and is explained without doubt by an under-
estimation of the potential risks of tobacco dependency.
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CONCLUSION: Young people are a population whose
dependency level is mainly low or moderate, a fact that
enables—with appropriate but generalised mobilization
(doctor, educator, pharmacist, family)—a smoking cessa-
tion attempt to succeed.
PCV55
SMOKING DEPENDENCY:AUDIT CARRIED OUT
AMONG THE UNDER 25 GROUP
Taïeb C1, Piergiovanni J2, Myon E1
1Programmes Pharmaco Economiques Pierre Fabre,
Boulogne Billancourt, France; 2Centre de Formation Ste
Cecile, Albi, France
OBJECTIVE: As part of an environment program 
(outcomes program) on smoking cessation, it seemed
interesting to study young smokers under the age of 25.
METHOD: A special questionnaire was distributed to
them via the “Student” supplement of a French regional
weekly newspaper (Tarn Libre), which they were asked
to return by post. RESULTS: The ﬁrst results concerned
the ﬁrst 50 questionnaires returned. Average age: 17.5
years; average weight: 56 kilos; average height: 1,67m.
In our sample, 92% were students, 86% declared them-
selves to be exposed to other people’s smoke and only
37% said they took part in a sporting activity. Age 
at which tobacco dependency began was 13 years; 
98% smoked cigarettes—versus 2% a cigar or pipe); the
average daily consumption was 10 cigarettes; of these,
65% wished to stop smoking, but only 38% had already
made an attempt at smoking cessation. Only 30%,
however, said that they had been asked spontaneously by
their doctor about their desire to stop smoking (minimum
advice) In the Fagerström test, 48% had low or no depen-
dency; 48% had moderate dependency and only 2% had
heavy dependency. CONCLUSION: This pilot study 
conﬁrmed that tobacco dependency is occurring at an
increasingly early age; that tobacco dependency in young
people is low or moderate, and that there is little 
management of tobacco dependency in young people by
doctors.
PCV56
ALLOCATION OF RESOURCES BETWEEN
SMOKING CESSATION METHODS AND
PHARMACEUTICAL TREATMENT OF
HYPERCHOLESTEROLEMIA BASED ON 
COST-EFFECTIVENESS AND THE SOCIAL
WELFARE FUNCTION
Plans-Rubió P
Departament de Sanitat of Catalonia, Barcelona, Spain
OBJECTIVE: The objective of the health system is to
achieve an efﬁcient and equitable allocation of scarce
health resources. In this study, a particular social welfare
function was used to decide the optimal allocation of
resources between smoking cessation methods (medical
advice, nicotine gum and nicotine patches) for smo-
kers and 20–80mg/day lovastatin (HMG-CoA reductase
inhibitor) for individuals with hypercholesterolemia.
METHODS: Parameter epsilon determining the exact
form of the social welfare function is >0 when society has
aversion to inequality in the distribution of health gains
between two patient groups, while it is equal to 0 when
there is no aversion. This parameter was determined using
a questionnaire to assess preferences concerning the 
efﬁciency-equity trade-off in a group of health mana-
gers. Based on these preferences, a higher priority should
be given to the preventive intervention associated with 
a value of epsilon consistent with that from the social
welfare function. RESULTS: A value of epsilon = 1.6 was
obtained for the social welfare function. Values of epsilon
obtained for different preventive interventions were
2.9–1.8 for medical advice for smoking cessation and
20–80mg/day lovastatin, 0.9–0.15 for nicotine gum and
20–80mg/day lovastatin, and 0 for nicotine patch 
for smoking cessation and 20–80mg/day lovastatin. The
highest value of epsilon was obtained for the interven-
tion using medical advice for smoking cessation and 
20mg/day lovastatin for hypercholesterolemia, with 2.9
in men and 2.4 in women. A higher priority should 
be given to the intervention using medical advice for
smoking cessation and 20–80mg/day lovastatin for
hypercholesterolemia than to interventions using nicotine
substitution therapies and 20–80mg/day lovastatin.
CONCLUSION: Lovastatin treatment of hypercholes-
terolemia should have a higher priority than nicotine 
substitution therapies for smoking cessation based on
cost-effectiveness and the social welfare function.
PCV57
IMPLICATIONS OF TREATMENT GUIDELINES:
WHAT STATINS DO WE REALLY NEED?
Haiderali A1, Rocchi A2
1AstraZeneca Canada, Mississauga, ON, Canada; 2Axia
Research, Hamilton, ON, Canada
OBJECTIVES: New treatment recommendations 
describe aggressive lipid-lowering goals to maximize 
cardiovascular-event risk reduction for a broad popula-
tion. This analysis determined what statin doses would
be required to achieve treatment goals in a Canadian
population. METHODS: Canadian treatment guidelines
were reviewed and combined with population-based data
on blood lipid levels to determine the percentage reduc-
tion in LDL-C required to achieve treatment goals. Efﬁ-
cacy of statins was determined from the literature. The
statin dose required for patients to achieve LDL-C reduc-
tion goal was reported. RESULTS: The Canadian
1985–1990 Heart Health Surveys reported that 18% of
men and 17% of women had high blood lipid levels, with
a total cholesterol £6.2mmol/L (corresponding to an
approximate LDL-C level £4.7mmol/L). Canadian 
guidelines dictate that adults with very high risk of car-
diovascular events (those with a history of cardio-
